Arbitel Plus Tablet (Telmisartan + Hydrochlorothiazide) – ACI Limited

1. About Arbitel Plus (Telmisartan 80 mg + HCT 12.5 mg)

Arbitel Plus Tablet contains Telmisartan 80 mg (maximum-dose ARB) and Hydrochlorothiazide 12.5 mg (thiazide diuretic), manufactured by ACI Limited, Bangladesh. This fixed-dose combination (FDC) delivers two complementary antihypertensive mechanisms in a single once-daily tablet: RAAS blockade from telmisartan and diuretic/natriuretic action from hydrochlorothiazide.

The ARB + thiazide combination is one of the most widely used dual antihypertensive regimens globally, providing additive blood pressure reduction (~8–12 mmHg additional systolic vs monotherapy) and is endorsed by all major hypertension guidelines. The diuretic component of Arbitel Plus activates the RAAS — which telmisartan simultaneously suppresses — creating complementary synergy: HCT activates angiotensin II production, telmisartan blocks it — amplifying the antihypertensive effect of both drugs.

2. Mechanism of Action

Telmisartan 80 mg (ARB): Selectively blocks AT1 receptors → inhibits angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium retention → reduces peripheral resistance and blood volume. 24-hour duration from once-daily dosing. Additional PPAR-γ partial agonism with metabolic benefits.

Hydrochlorothiazide 12.5 mg (Thiazide Diuretic): Inhibits Na+/Cl− co-transporter in the distal convoluted tubule → increases renal sodium and water excretion → reduces blood volume → lowers blood pressure. HCT also reduces peripheral resistance through mechanisms independent of volume depletion with long-term use. At 12.5 mg, provides antihypertensive effect with minimal metabolic disruption (compared to higher doses).

Synergy: HCT activates the renin-angiotensin system (compensatory response to volume depletion) — which telmisartan directly blocks. This prevents HCT’s loss of efficacy over time (RAAS escape) and produces greater BP reduction than either agent alone, while telmisartan counters HCT’s hypokalaemia by reducing aldosterone.

3. Indications

• Essential Hypertension requiring dual-class therapy (ARB + diuretic)
• Hypertension not controlled on telmisartan 80 mg alone
• Patients on separate telmisartan 80 mg + HCT tablets — FDC simplifies to one tablet
• Resistant/moderate-to-severe hypertension as part of triple regimen
• Oedematous hypertensive patients — diuretic component provides fluid offloading

4. Dosage and Administration

Standard: One tablet once daily, preferably in the morning (to avoid nocturia from diuretic). Take with or without food.

Titration: Generally initiated after patients are already on telmisartan 80 mg monotherapy (or 40 mg with HCT) that has proven insufficient. Maximum recommended telmisartan dose is 80 mg/day; maximum HCT antihypertensive dose 25 mg/day.

Take consistently at the same time each day. Morning dosing preferred.

5. Contraindications

• Hypersensitivity to telmisartan, HCT, or sulfonamides (cross-reactivity)
• Pregnancy (telmisartan teratogenic; HCT can cause foetal electrolyte disturbances)
• Severe renal impairment (eGFR <30 ml/min — HCT ineffective; telmisartan requires monitoring)
• Anuria; severe hepatic impairment
• Refractory hypokalaemia, hyponatraemia, hypercalcaemia
• Concurrent aliskiren in diabetes or eGFR <60 ml/min

6. Warnings and Precautions

Pregnancy: Strictly contraindicated. Telmisartan causes foetal toxicity; HCT causes foetal thrombocytopenia and electrolyte disturbances.

Electrolyte disturbances (HCT): Hypokalaemia most common (partially offset by telmisartan’s K+-sparing effect). Monitor Na+, K+, and Cl− at baseline and periodically. Risk of hypokalaemia is lower with 12.5 mg vs higher HCT doses.

Renal function: Monitor creatinine and eGFR. HCT reduces renal perfusion in CKD. Both components can cause acute kidney injury in bilateral renal artery stenosis or significant dehydration.

Glucose/Lipids (HCT): HCT may slightly raise blood glucose and triglycerides at higher doses. At 12.5 mg, metabolic effects are minimal but monitor in diabetic patients.

Gout: HCT raises uric acid — can precipitate gout attacks. Use with caution in patients with hyperuricaemia or gout history.

Hypotension: Volume-depleted patients at risk of first-dose hypotension from combined diuretic + ARB effect.

7. Side Effects

HCT (common): Hypokalaemia (attenuated by telmisartan), mild hyponatraemia, polyuria/nocturia, muscle cramps, dizziness.

Telmisartan (common): Dizziness, fatigue, headache, back pain, URTI, diarrhoea.

Uncommon: Hyperkalaemia (from telmisartan, partly offsetting HCT hypokalaemia), elevated uric acid, impaired glucose tolerance (HCT at low dose, minimal at 12.5 mg).

Rare: Photosensitivity (HCT), angioedema, hepatic dysfunction, HCT-induced pancreatitis.

8. Drug Interactions

• NSAIDs: Reduce antihypertensive efficacy of both components; increase renal impairment risk
• Lithium: Both HCT and telmisartan increase lithium levels — monitor levels carefully
• Digoxin: Telmisartan raises digoxin Cmax; HCT hypokalaemia increases digoxin toxicity — monitor
• K+-sparing agents/K+ supplements: Complex effect — HCT lowers K+, telmisartan raises K+; overall effect variable. Monitor K+
• Antidiabetics: HCT may reduce efficacy; adjust diabetes medication if needed
• Cholestyramine/colestipol: Reduce HCT absorption — give Arbitel Plus 1 hour before or 4–6 hours after

9. ARB + Thiazide: Evidence and Guidelines

ARB + thiazide is a guideline-endorsed first-line combination for hypertension. The ACCOMPLISH trial helped establish the importance of combination therapy, and multiple meta-analyses confirm ARB + diuretic provides ~8–12 mmHg additional systolic BP reduction vs monotherapy. The ARB component of Arbitel Plus also counters three common disadvantages of thiazide monotherapy: HCT-induced RAAS activation (telmisartan blocks it), HCT-associated hypokalaemia (telmisartan’s K+-sparing via aldosterone suppression offsets this), and worsening glucose control (telmisartan’s PPAR-γ activity modestly improves insulin sensitivity).

10. Arbitel Plus in Diabetic Hypertension

While the ARB + CCB (Arbitel AM) combination is often preferred in T2DM patients with nephropathy, the ARB + thiazide (Arbitel Plus) combination is appropriate for: diabetic patients with normal renal function who also have fluid overload, patients who require volume reduction in addition to RAAS blockade, or as a component of triple therapy (telmisartan + amlodipine + HCT). At HCT 12.5 mg, the metabolic effects on glucose and lipids are minimal. Telmisartan’s PPAR-γ partial agonism and ARB class renoprotection further support its use in diabetic patients.

11. Morning Dosing and Diuretic Timing

For optimal patient experience, Arbitel Plus should be taken in the morning. The hydrochlorothiazide diuretic effect peaks 4–6 hours after dosing — morning administration ensures diuresis occurs during waking hours and prevents nocturia (nighttime urination). Telmisartan’s 24-hour coverage means once-daily morning dosing provides continuous 24-hour antihypertensive effect regardless of timing.

12. ACI Limited Arbitel Plus Range

ACI’s Arbitel Plus range: Arbitel Plus 40+12.5 mg (telmisartan 40 mg + HCT 12.5 mg — starting dose) and Arbitel Plus 80+12.5 mg (telmisartan 80 mg + HCT 12.5 mg — target/maintenance dose). Both are once-daily FDC tablets for ARB + diuretic combination therapy.

13. Storage

• Below 30°C, cool, dry, protected from moisture and light
• Morning dosing recommended. Original blister pack.
• Do not use after expiry.

Frequently Asked Questions (FAQ)

Q1: What is Arbitel Plus (Telmisartan + HCT) used for?

Arbitel Plus combines Telmisartan 80 mg (ARB — blocks angiotensin II) and Hydrochlorothiazide 12.5 mg (thiazide diuretic — removes excess sodium/water) for hypertension not controlled on ARB monotherapy alone. The two drugs work synergistically: HCT activates the renin-angiotensin system as a compensatory response to fluid loss, which telmisartan simultaneously suppresses — amplifying the blood pressure-lowering effect. It is used when telmisartan 80 mg alone is insufficient for BP control, or for patients already on both drugs separately wishing to simplify to one tablet.

Q2: Will Arbitel Plus affect my potassium levels?

Both components have opposing effects on potassium: HCT lowers potassium (hypokalaemia risk), while telmisartan raises potassium (hyperkalaemia via aldosterone suppression). In most patients, these effects partly cancel out, resulting in near-normal potassium levels on Arbitel Plus compared to HCT alone. However, individual variation occurs. Monitor serum potassium at baseline and periodically — especially in patients with CKD, on K+-sparing diuretics (spironolactone), K+ supplements, or ACE inhibitors. Report muscle cramps (sign of low K+) or irregular heartbeat to your doctor.

Q3: Can diabetic patients take Arbitel Plus?

Yes, with some caveats. Hydrochlorothiazide at higher doses can impair glucose control and insulin sensitivity. However, at the low 12.5 mg dose in Arbitel Plus, metabolic effects are minimal in most diabetic patients. Telmisartan’s PPAR-γ partial agonism may partially offset any glucose-worsening effect. Monitor blood glucose more closely when initiating Arbitel Plus in T2DM patients. Diabetic patients with significant CKD (<eGFR 30) should not use Arbitel Plus as HCT becomes ineffective below this threshold — use Arbitel Plus 80 mg telmisartan alone (Arbitel 80 mg) or with amlodipine (Arbitel AM 5+80 mg) instead.

Q4: Why should Arbitel Plus be taken in the morning?

The hydrochlorothiazide component of Arbitel Plus produces its peak diuretic effect (increased urine output) within 4–6 hours of ingestion. Taking Arbitel Plus in the morning ensures this diuresis occurs during the day when it is convenient, rather than at night when it would disrupt sleep (nocturia). Telmisartan’s antihypertensive effect lasts the full 24 hours, so morning dosing provides complete day-and-night BP coverage. Consistent same-time daily dosing is important for stable blood pressure control.